Context Therapeutics add new CMO

pharmafile | July 24, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Context Therapeutics, biotech, drugs, pharma, pharmaceutical 

Context Therapeutics, a biotech company that focuses on the development of treatments for Sigma1-related diseases, has announced that a new Chief Medical Officer has joined its team. Erad Gilles, most recently of Invivis Pharmaceuticals, will take up the position permanently after previously having operated as Consulting CMO for the company.

Gilles role prior to joining Context was as founder of Invivis, as well as performing the role of Chief Medical Officer – a company that developed an anti-progestin therapy and biomarker that was licensed by Arno Therapeutics.

Beyond this, he has a varied working history as a Director of Oncology at Roche for three years, spending six years as Vice President of Oncology at Pfizer before moving onto roles at Sanofi and J&J.

“Context is a great innovator in Sigma1 biology and therapeutics, and the Company is emblematic of the science-driven, precision medicine approach that will bring about much-needed therapies for cancer patients,” said Dr Gilles on his appointment. “I am delighted to have the opportunity to lead Context’s clinical programs at such a pivotal time for the Company.”

“We are excited to welcome Erard to Context as chief medical officer,” said Martin Lehr, Chief Executive Officer. “His extraordinary medical and scientific expertise and strong relationships in the oncology community, both within the US and Europe, will be invaluable as Context pursues its mission to change the world for patients with advanced cancer through bold and innovative science.”

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Zumutor’s cancer drug trial cleared by FDA

On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …

Latest content